BPMC News and Press, Blueprint Medicines Corporation From 07/19/23

Blueprint Medicines to Report Second Quarter 2023 Financial Results on Wednesday, August 2, 2023 PR Newswire CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call a...

2023-07-14 11:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The past year provided a peek into the future of biotech and healthcare. Megafirms like Medtronic (NYSE: MDT ) led the way, partnering with tech giants such as...

2023-06-12 09:30:39 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements. Drug stocks with ongoing clinical ...

2023-06-04 08:45:00 ET In the often-volatile world of biotech stocks, shares of small-cap Blueprint Medicines (NASDAQ: BPMC) have proven surprisingly steady over the past 12 months. But the stock could be gearing up for a bull run. That's thanks to an expanded set of prescription gu...

Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting PR Newswire -- Breadth of pipeline featured in multiple early clinical data presentations, reflecting diversity of fundamental growth drivers across development prog...

NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis PR Newswire -- First and only treatment approved by FDA for indolent SM -- CAM...

FDA Approves AYVAKIT® (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis PR Newswire -- For the first time, patients with indolent SM have a medicine that treats the primary disease driver and is proven to provide broad and durable symptom re...

2023-05-09 02:28:28 ET Summary Blueprint Medicines focuses on developing precision therapies for genomically defined cancers and blood disorders, with two approved drugs and multiple ongoing programs. The company's stock has risen by 25% since the previous analysis, supported by s...

2023-05-04 12:51:08 ET Blueprint Medicines Corporation (BPMC) Q1 2023 Earnings Conference Call May 4, 2023 08:00 AM ET Company Participants Jenna Cohen - Senior Director and Head, Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Comm...

2023-05-04 07:55:35 ET Blueprint Medicines press release ( NASDAQ: BPMC ): Q1 GAAP EPS of -$2.15 beats by $0.51 . Revenue of $63.28M (+0.9% Y/Y) beats by $21.43M . Cash Position: As of March 31, 2023, cash, cash equivalents and investments were $961.3 million, ...